The following signs are specific to transitional cell, urinary bladder cancer:\n- Blood or leukocytes in the urine\n- Pain in the back, or pain in the loins\n- Weight loss\n- Urine of a dark hue or tarry\n- Persistent and intense purging\n\nCarcinoma, transitional cell has a variable presentation. It can present either as a mass on the bladder, a change in urine characteristics or symptoms in a previously asymptomatic person.
There have been a number of different names for a very similar entity but there remains much ambiguity and variation of terminology in this area. The name carcinoma, transitional cell is the appropriate one for a disease where differentiation between squamous epithelial cells and urothelial cells is present.
Radical cystectomy for carcinoma transitional cell or squamous cell of the urinary bladder is the recommended adjuvant therapeutic approach to patients with Stage T3N0M0 urothelial carcinoma. However, it can be used in select patient with Stage T2N0M0, T3N0M0 and T3N0M1 urothelial carcinoma.
The causation of carcinoma, transitional cell depends on genetics. It is likely for these diseases to be related and it is important to diagnose and treat any cancer in the urinary tract to avoid the risk of recurrence afterwards. Even with curative treatment, the recurrence of transitional cell carcinoma is common.
T1 and T2 are generally treated with surgery. A minority of the patients will have recurrent carcinoma, so the patients should be followed up regularly for surveillance.
Nearly 500,000 people are diagnosed with transitional cell carcinoma of the bladder each year in the US. The overall 5-year survival rate in this disease is 67%; the median survival is 7 months. The survival rates for stage 0 and 1 bladder cancer were 62% and 55%, respectively.
Oral grt-c901 is promising for use as a first line treatment for patients with metastatic papillary transitional cell carcinoma as the only objective indicator of improved survival in this population of patients is long term survival. Additional ongoing clinical trials are now needed for further evaluation of the potential clinical benefits of grt-c901. Clinicaltrials.gov number: NCT01093950.
Grt-c901 is safe and effective for the treatment of patients with advanced carcinoma of the larynx. Data from a recent study of this randomized and blinded trial, although encouraging overall, should be interpreted cautiously in view of the relatively small number of patients included, as well as the different ways in which the study was planned and carried out.
The grt-c901 is an exciting new cancer treatment compound that may be capable of controlling cancers at a very low dosage. Proteins for Cancer Research, 4(3): 277–280, 2004(4). [Power(http://www.withpower.
Carcinoma, transitional cell predominates as the initial diagnosis (51%). It is recommended that the diagnosis is established on a combination of cystoscopy and pathological examination of the urine for malignant cells.
This was not a large sample, and it may not necessarily reflect true incidence patterns, but the data can nonetheless provide insight into the incidence and prevalence of the disease to the medical community.
In a recent study, findings of the current study suggest that the combination of grt-c901 and trichostatin A may be a well-tolerated and effective therapy for metastatic transitional cell carcinoma.